PMID- 36131910
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20231105
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Individual HLA heterogeneity and its implications for cellular immune evasion in 
      cancer and beyond.
PG  - 944872
LID - 10.3389/fimmu.2022.944872 [doi]
LID - 944872
AB  - Structural and functional variability of human leukocyte antigen (HLA) is the 
      foundation for competent adaptive immune responses against pathogen and tumor 
      antigens as it assures the breadth of the presented immune-peptidome, 
      theoretically sustaining an efficient and diverse T cell response. This 
      variability is presumably the result of the continuous selection by pathogens, 
      which over the course of evolution shaped the adaptive immune system favoring the 
      assortment of a hyper-polymorphic HLA system able to elaborate efficient immune 
      responses. Any genetic alteration affecting this diversity may lead to 
      pathological processes, perturbing antigen presentation capabilities, T-cell 
      reactivity and, to some extent, natural killer cell functionality. A highly 
      variable germline HLA genotype can convey immunogenetic protection against 
      infections, be associated with tumor surveillance or influence response to 
      anti-neoplastic treatments. In contrast, somatic aberrations of HLA loci, 
      rearranging the original germline configuration, theoretically decreasing its 
      variability, can facilitate mechanisms of immune escape that promote tumor growth 
      and immune resistance. The purpose of the present review is to provide a unified 
      and up-to-date overview of the pathophysiological consequences related to the 
      perturbations of the genomic heterogeneity of HLA complexes and their impact on 
      human diseases, with a special focus on cancer.
CI  - Copyright (c) 2022 Pagliuca, Gurnari, Rubio, Visconte and Lenz.
FAU - Pagliuca, Simona
AU  - Pagliuca S
AD  - Translational Hematology and Oncology Research Department, Cleveland Clinic, 
      Cleveland, OH, United States.
AD  - Service d'hematologie Clinique, Hopital Brabois, CHRU Nancy and CNRS UMR 7365 
      IMoPa, Biopole de l'Universite de Loarraine, Vandoeuvre les Nancy, France.
FAU - Gurnari, Carmelo
AU  - Gurnari C
AD  - Translational Hematology and Oncology Research Department, Cleveland Clinic, 
      Cleveland, OH, United States.
AD  - Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, 
      Italy.
FAU - Rubio, Marie Therese
AU  - Rubio MT
AD  - Service d'hematologie Clinique, Hopital Brabois, CHRU Nancy and CNRS UMR 7365 
      IMoPa, Biopole de l'Universite de Loarraine, Vandoeuvre les Nancy, France.
FAU - Visconte, Valeria
AU  - Visconte V
AD  - Translational Hematology and Oncology Research Department, Cleveland Clinic, 
      Cleveland, OH, United States.
FAU - Lenz, Tobias L
AU  - Lenz TL
AD  - Research Unit for Evolutionary Immunogenomics, Department of Biology, University 
      of Hamburg, Hamburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220905
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Antigens, Neoplasm
MH  - HLA Antigens/genetics
MH  - Histocompatibility Antigens Class I
MH  - Histocompatibility Antigens Class II
MH  - Humans
MH  - *Immune Evasion
MH  - *Neoplasms/genetics
PMC - PMC9483928
OTO - NOTNLM
OT  - HLA
OT  - HLA evolutionary divergence
OT  - immune escape
OT  - immunopeptidome
OT  - tumor surveillance
COIS- TL is co-inventor on a patent application for using HED as a prognostic marker 
      for immunotherapy success. The remaining authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be constructed as a potential conflict of interest.
EDAT- 2022/09/23 06:00
MHDA- 2022/09/24 06:00
PMCR- 2022/01/01
CRDT- 2022/09/22 03:28
PHST- 2022/05/16 00:00 [received]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/09/22 03:28 [entrez]
PHST- 2022/09/23 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.944872 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 5;13:944872. doi: 10.3389/fimmu.2022.944872. eCollection 
      2022.